Global Malignant Glioma Market

Global Malignant Glioma Market Size Insights Forecasts to 2035

• The Global Malignant Glioma Market Size Was valued at USD 1.3 Billion in 2024
• The Global Malignant Glioma Market Size is Expected to Grow at a CAGR of around 7.26% from 2025 to 2035
• The Worldwide Malignant Glioma Market Size is Expected to Reach 2.3 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Malignant Glioma Market Size Was Worth Around USD 1.3 Billion In 2024 And Is Predicted To Grow To Around USD 2.3 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 7.26% From 2025 To 2035. The global malignant glioma market offers future growth opportunities because of increasing disease occurrence and the rising use of targeted treatments which include Temozolomide and the progress of immunotherapy treatments which contain Bevacizumab and the boost in clinical research activities and the creation of customized medical solutions and the development of healthcare facilities throughout the globe.

 

Market Overview

The global malignant glioma market refers to the worldwide industry which develops and produces and sells treatments for malignant glioma. These treatments include chemotherapy with Temozolomide and targeted therapy and radiation therapy and immunotherapy and new biologics for aggressive brain tumors. Additionally, the malignant glioma market presents numerous opportunities, particularly in the realm of research and development. The emergence of precision medicine enables doctors to create personalized treatment plans which match the specific genetic characteristics of each patient's tumor. The shift to personalized medical treatment will increase demand for biomarker studies and targeted drug treatments which will create major changes in market operations. Moreover, the sector is currently receiving funding because of its heightened interest in treatment methods which combine different therapeutic approaches. Clinical trials which study how chemotherapy drugs work together with immunotherapy treatments are experiencing increased development which shows growing interest in this research area.

 

Report Coverage

This research report categorizes the malignant glioma market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the malignant glioma market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the malignant glioma market. 

 

Driving Factors

The malignant glioma market receives its current advancement through multiple factors. The most important factor driving market growth is the worldwide increase of brain tumor cases. The World Health Organization estimates that brain tumors account for approximately 2.5% of all new cancer cases worldwide every year. The increasing number of patients with this condition has led pharmaceutical companies to increase their research and development spending which results in the creation of new treatments. Furthermore, advancements in diagnostic technologies, such as MRI and PET scans, are enabling earlier detection of malignant gliomas, which is critical for effective treatment and improving patient prognosis.

 

Restraining Factors

The global malignant glioma market encounters multiple limitations because of expensive treatment methods and ineffective existing treatments which include Temozolomide and the difficulties of blood-brain barrier penetration and the serious adverse effects and the delayed diagnosis and tumor recurrence and the strict rules of regulatory body approval.

 

Market Segmentation

The malignant glioma market share is classified into Type and Treatment Modalities

 

• The glioblastoma multiforme (GBM) segment dominated the market in 2024, approximately 55% and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the malignant glioma market is divided into glioblastoma multiforme (GBM) and anaplastic astrocytoma. Among these, the glioblastoma multiforme (GBM) segment dominated the market in 2024, approximately 55% and is projected to grow at a substantial CAGR during the forecast period. GBM needs extensive medical treatment which includes surgical procedures and radiation therapy and chemotherapy with Temozolomide because its incidence rate and aggressive disease progression and low survival rates exceed those of anaplastic astrocytoma. The segment experiences growth because research activities and clinical trials continue to increase.

• The tumor resection segment accounted for the largest share in 2024, approximately 65% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the treatment modalities, the malignant glioma market is divided into surgery and tumor resection. Among these, the tumor resection segment accounted for the largest share in 2024, approximately 65% and is anticipated to grow at a significant CAGR during the forecast period. The primary treatment for tumor size reduction and symptom relief and patient survival improvement. The adoption of neurosurgical techniques and imaging-guided resections and post-operative care advancements has driven market growth while establishing these procedures as the preferred treatment method.

 

Regional Segment Analysis of the Malignant Glioma Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the malignant glioma market over the predicted timeframe.

North America is anticipated to hold the largest share of the malignant glioma market over the predicted timeframe. The region experiences multiple healthcare advantages which include advanced medical facilities, diagnostic tool availability, and innovative treatment options, along with substantial financial support from both government and private sectors for oncology research. The regional market growth is driven by increasing clinical trials and awareness programs, together with the rising implementation of targeted therapies.

 

Asia-Pacific is expected to grow at a rapid CAGR in the malignant glioma market during the forecast period. The market expansion in China, India, and Japan occurs because of three factors which include enhanced diagnostic capabilities and government efforts to establish cancer treatment centers and the increasing number of patients who require cancer care.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the malignant glioma market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Amgen Inc.
• AstraZeneca plc
• Bristol Myers Squibb
• Eli Lilly and Company
• Johnson & Johnson (Janssen Pharmaceuticals)
• Takeda Pharmaceutical Company Ltd.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In November 2025, the FDA granted orphan drug designation to tinostamustine, a novel therapy that combined alkylating and HDAC?inhibiting actions, supporting its development for patients with malignant glioma and offering incentives that encouraged trials in aggressive brain tumors.”

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the malignant glioma market based on the below-mentioned segments: 

 

Global Malignant Glioma Market, By Type 

• Glioblastoma Multiforme (GBM)
• Anaplastic Astrocytoma

 

Global Malignant Glioma Market, By Treatment Modalities

• Surgery
• Tumor Resection

 

Global Malignant Glioma Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

Q: What is the expected growth of the global malignant glioma market?

A: The market is projected to grow from USD 1.3 Billion in 2024 to USD 2.3 Billion by 2035 at a CAGR of 7.26%.

 

Q: Which type dominates the malignant glioma market?

A: Glioblastoma multiforme (GBM) dominated in 2024 with approximately 55% share due to aggressive progression, high incidence, low survival, and extensive treatment requirements.

 

Q: What is the largest treatment modality segment?

A: Tumor resection accounted for 65% share in 2024, driven by surgical reduction of tumor size, symptom relief, advanced neurosurgical techniques, and imaging-guided procedures.

 

Q: Which region holds the largest market share?

A: North America leads due to advanced healthcare infrastructure, diagnostic availability, targeted therapies, clinical trials, awareness programs, and government/private oncology funding.

 

Q: Why is Asia-Pacific growing rapidly in this market?

A: Growth is fueled by enhanced diagnostics, government cancer treatment initiatives, and increasing patient population in countries like China, India, and Japan.